Recent:Yotsuyanagi.
Ensitrelvir has been officially adopted
in 1 country.
Submit updates/corrections .
Jul 13 |
et al., medRxiv, doi:10.1101/2023.07.11.23292264 | Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild-to-Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial |
| 11% faster recovery (p=0.3) and 49% improved viral clearance (p=0.001). RCT 1,821 COVID-19 outpatients in Japan, Vietnam, and South Korea, showing improved viral clearance and improved recovery (significant for patients treated within 3 days of onset) with ensitrelvir. Only 2 hospitalizations were reported, w.. | ||
Feb 10 |
et al., Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkad027 | Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo |
| In Vitro and animal study comparing nirmatrelvir and ensitrelvir, showing similar efficacy in vitro, and equal or better efficacy of ensitrelvir in vivo (with similar unbound-drug plasma concentrations). | ||
Dec 7 2022 |
et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac933 | Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study |
| 9% improved recovery (p=0.28) and 32% faster viral clearance (p=0.0001). RCT 428 COVID-19 patients in Japan showing faster viral clearance and improved recovery with ensitrelvir. | ||
May 17 2022 |
et al., medRxiv, doi:10.1101/2022.05.17.22275027 | A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-like Protease Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part |
| 45% improved viral clearance (p=0.002). RCT 69 patients in in Japan, showing faster viral clearance with ensitrelvir. 5-day ensitrelvir (375mg on day 1 followed by 125 mg daily or 750mg on day 1 followed by 250mg daily). | ||
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.